Sotatercept

• SOFAPI Pending
  2025-520731-17-02 Phase III 1 country Centre Hospitalier Regional Et Universitaire De Brest
• RECOMPENSE: Right vEntricular COMPENsation with SotatercEpt. A prospective single arm open label phase IV study to evaluate the effects of s… Recruiting
  2024-512543-23-00 Phase IV 1 country Amsterdam UMC Stichting
• A Long-term Follow-up Study of Sotatercept for PAH Treatment Recruiting
  2023-509138-21-00 Phase III 14 countries Acceleron Pharma Inc.
• Sotatercept in Children with Pulmonary Artery Hypertension on Standard of Care Recruiting
  2023-504861-22-00 Phase II 5 countries Merck Sharp & Dohme LLC
• A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-038) Ended
  2025-521970-33-00 Phase III 13 countries Merck Sharp & Dohme LLC
• A clinical study of sotatercept in people with pulmonary arterial hypertension Ended
  2024-518687-12-00 Phase II 7 countries Merck Sharp & Dohme LLC
• A clinical study of sotatercept in people with pulmonary hypertension (MK-7962-023) Ended
  2024-515773-99-00 Phase II 7 countries Merck Sharp & Dohme LLC
• A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-024) Ended
  2024-512278-92-00 Phase II 8 countries Merck Sharp & Dohme LLC
• A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension (PAH) Patients. Ended
  2023-509139-16-00 Phase III 13 countries Acceleron Pharma Inc.
• A Phase 2 Study of Sotatercept for Combined Postcapillary and Precapillary Pulmonary Hypertension Treatment Ended
  2023-509141-12-00 Phase II 7 countries Acceleron Pharma Inc.
• A study to evaluate Sotatercept in Participants with PAH WHO FC III or FC IV at High Risk of Mortality Ended
  2023-509140-10-00 Phase III 6 countries Acceleron Pharma Inc.

Showing 1–11 of 11 trials